This is the rolling coronavirus story for Thursday 11 March 2021
Read More for details.
Vaccination stats published yesterday afternoon with data up to 9 March - now includes over 1M more vaccines having been delivered - around 141,000 more doses administered in the last 24 hours - around 36,000 more people have had 2nd dose in the last 24 hours
The situation in the Poniente region is different? - article from yesterday
"The evolution of the covid in the Poniente is different, it passes through a plateau"
"It has not fallen from that high and it is difficult to lower it," says the district director, Queti Quesada
Although it has already dropped from the 250 covid rate, the West of Almeria currently has the highest incidence of the three health districts of the province, with 223.4 cases per 100,000 inhabitants in 14 days and is the second Andalusian district with the highest rate accumulated in the same period.
According to Enriqueta Quesada, director of the Poniente health district, the region is experiencing an evolution of the coronavirus "completely different" from the rest of the province, where very high and low peaks have been registered.
“Here, however, it has not fallen from as high as it has happened in Almería or the Levante, we have a plateau that has meant that we have never reached high rates and that now, although the incidence continues to decrease, it does so more slowly and is more difficult to reduce it ”, he explains. She says she does not have an explanation for this fact, although she points out that it may be due to the specific characteristics and conditions of her population. However, for her the fact that the district is on this plateau is not her main concern.
Easter "What really worries me now is what will happen at Easter," she warns. In this sense, she considers complicated the possibility that the district lowers its alert level to relax the restrictions.
“To lower alert level 2, a series of indicators are taken into account, such as incidence, occupation of hospitals and intensive care units, and today the Hospital de Poniente maintains an ICU occupation of 123 percent, ”he says. Regarding the hospital occupancy of Covid patients in the ejidense hospital center, it now stands at 15%, but with the ICU data it seems difficult for them to fall to the levels required to improve the alert level.
One of the problems, warns ‘Queti’ Quesada, not only in the ejidense hospital, but in Almería in general, is that the province has very few ICU beds. In the Hospital de Poniente there are only 20 (by 35 in Torrecárdenas and 10 in Huércal-Overa), which means that with a not too high number of patients the percentage of occupancy skyrockets to very high limits.
Vaccination For the rest, the great "priority" for the director of the Poniente district is vaccination against the covid and all her efforts "are now put into it." These days almost 400 agents of the Civil Guard of Roquetas are being vaccinated in three shifts, while trying to maintain the vaccination levels of the priority groups established by the Ministry of Health, although currently vaccinations have had to be stopped in some of them due to supply problems.
Despite criticism from different sectors of the population about the criteria for the vaccination order, Queti Quesada considers them "logical" and "not very wrong", insofar as priority has been given to the most vulnerable groups.
This has led, for example, to the fact that there is only one user of a nursing home in Poniente, in Vícar, who has not received the second dose. With this, it has been achieved that today not a single major of the centers of the West is infected by coronavirus.
Virtual consultations In the months that she has served as head of the Poniente health district, her new director has had time to face “pending tasks”, mainly due to the pandemic, which has set other priorities.
Thus, he affirms, the development of virtual consultations for doctors and patients in Primary Care is being completed, which, in his opinion, represents an important advance for the adequate treatment of patients in cases, which are also many, in those cases. that their physical presence is not needed to be cared for by doctors, especially in situations like the one we live in this pandemic. Thus, these virtual consultations in different specialties are already underway, while in others the details are being finalized to start working shortly.
Stats for the last 24 hours - 196 more cases and 3 more deaths
The worst day of this March leaves about 200 cases, in addition to 3 deaths
The data is also the most negative of the last three weeks in terms of daily infections
The province of Almería this Thursday touches the 200 positives of coronavirus in which it is the worst day in terms of infections so far in March. In addition, we must regret 3 new deaths.
These are data extracted from the latest report from the Andalusian Institute of Statistics and Cartography (IECA), which indicates that in the last 24 hours there have been 196 cases detected through PDIA tests (PCR technique or rapid antigen test). To these we must add 1 more case after carrying out a rapid antibody test.
So far this month, the highest number of daily infections had occurred on Saturday, March 6, when the Junta de Andalucía reported 185 positives. And you have to go to Thursday, February 25, to find a bigger one, but still below that of March 11: then there were 191 positives.
The 196 positives by PDIA of this March 11 not only represent the most negative data of the month but also of the last three weeks, since on Friday, February 19, there were 227 positives on the same day.
Also for the sixth consecutive day, deaths due to Covid-19 are reported. There are three residents of the province who have lost their lives due to the disease, which leaves a total of 52 deaths so far this month and 687 since the start of the pandemic.
More positive is the data on hospitalizations: 5 people have been admitted in the last 24 hours in Almería, although 3 of them have done so to undergo Intensive Care. Regarding the cured, on Thursday there are 111 people who have received the epidemiological discharge.
With these data, the coronavirus cases that are still active throughout the province are 13,189: it is the difference between all confirmed cases since the beginning of the health crisis (46,444) and the difference between the total number of deaths (687 ) and recovered (32,568). On Tuesday the active cases were 13,172.
If we look at the accumulated incidence, the rate in the province stands at 216.5 cases in the last 14 days per 100,000 inhabitants (yesterday it was 239). In the capital, this marker stands on March 11 at 240.4. And by health districts, which will be analyzed every Thursday (taking this and other factors into account), this is the situation: the district of Almería has a cumulative rate of 220.8; that of Levante-Alto Almanzora of 180.8; and that of Poniente of 231.6.
In the absence of the meeting of the High Impact Public Health Alert Committee of Almería that this Thursday will define if any of the health areas of Almería can lower the level and, therefore, open trade and hospitality beyond six o'clock in the late, only the district of Levante-Alto Almanzora seems to have any chance in this regard.
Cumulative Stats from Almería 360
El Ejido now has 278.2 cases (approximately 7 fewer than yesterday) per 100,000 inhabitants based on the 14 day average (red for increase; blue for decrease)
Poniente Region now has 231.5 cases (approximately 8 more than yesterday) per 100,000 inhabitants based on the 14 day average (red for increase; blue for decrease)
Janssen vaccine approved for use in the EU
The fourth vaccine arrives: the European Medicines Agency endorses Janssen's
The vaccine has a single dose and can be given from 18 years of age
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the granting of a conditional marketing authorization for the Janssen single dose vaccine against COVID-19 in people 18 years of age and older.
Following a "comprehensive" evaluation, the EMA has concluded by consensus that the vaccine data is "robust and meets the criteria for efficacy, safety and quality." Thus, it becomes the fourth recommended vaccine in the EU to prevent COVID-19.
"With this latest positive opinion, the authorities throughout the European Union will have another option to combat the pandemic and protect the lives and health of its citizens," commented the executive director of the EMA, Emer Cooke, who stressed that "This is the first vaccine that can be used in a single dose."
According to the EMA, the European Commission will now "accelerate the decision-making process to grant conditional marketing authorization, which will allow the launching of vaccination programs throughout the EU."
Results from a clinical trial involving people from the United States, South Africa, and Latin American countries revealed that the vaccine is effective in preventing the disease in people 18 years of age and older. More than 44,000 people participated in this study. Half received a single dose of the vaccine and the other half received a placebo (a dummy injection). People did not know if they had been given the COVID-19 Janssen vaccine or the placebo.
The trial found a 67 percent reduction in the number of symptomatic COVID-19 cases two weeks later (116 cases out of 19,630 people) compared to people who received placebo (348 out of 19,691 people).
Side effects and how it works
Side effects were generally mild or moderate and disappeared within a couple of days after vaccination. The most common were injection site pain, headache, tiredness, muscle pain, and nausea. In any case, the EMA clarifies that "the safety and efficacy of the vaccine will continue to be monitored as it is used in the EU, through the pharmacovigilance system and additional studies carried out by the company and the European authorities."
This Janssen vaccine works by preparing the body to defend itself against the COVID-19 virus, SARS-CoV-2. It is made up of another virus (an adenovirus) that has been modified to contain the gene to make the spike protein of the coronavirus. This is a protein that the virus needs to enter the cells of the body.
Adenovirus transmits the SARS-CoV-2 gene to the cells of the vaccinated person. The cells can then use the gene to make the spike protein. The person's immune system will recognize the spike protein as foreign and will produce antibodies and activate T lymphocytes (white blood cells) to attack it. Later, if the person comes into contact with SARS-CoV-2, the immune system of the vaccinated person will recognize the spike protein of the virus and will be ready to defend the body against it. The adenovirus in the vaccine cannot reproduce and does not cause disease.
Conditional marketing authorization is used as a rapid authorization procedure to speed up the approval of treatments and vaccines during public health emergencies in the EU. Thus, they allow the authorization of drugs that satisfy an unmet medical need on the basis of less complete data than those normally required. "This occurs when the benefit of the immediate availability of a drug or vaccine for patients outweighs the risk inherent in the fact that not all the data is available yet," he justifies.
In this way, it ensures that the approved medicine or vaccine meets the EU's "rigorous standards" for efficacy, safety and quality, and that it is manufactured in approved and certified facilities, in accordance with the "strict" pharmaceutical standards of large-scale production. Once granted, companies must provide more data from ongoing or new studies within pre-established timeframes to confirm that the benefits continue to outweigh the risks.
Upcoming regional border closures and other measures for Father's Day and Easter